IBA announces a partnership to develop digital technologies to improve the affordability and clinical value of proton therapy

IBA announces a partnership to develop digital technologies to improve the affordability and clinical value of proton therapy

Press releases may be edited for formatting or style | May 06, 2019 Rad Oncology Proton Therapy
Louvain-la-Neuve, Belgium, May 6th, 2019 - IBA (Ion Beam Applications SA), the world’s leading provider of proton therapy solutions for the treatment of cancer, is pleased to announce a research agreement with Skandionkliniken, Université Catholique de Louvain and Telemis aimed at accelerating installation, optimizing service and improving clinical operations.

New developments in machine learning, statistics and pattern analysis allow providing clinical and operations staff with meaningful outcomes from the data generated by proton therapy systems.

The main objective of this program is to further improve treatment quality through personalized on-line adaptive therapy. Additionally, this project will also help to maximize the uptime and the patient throughput of the system while minimizing yearly maintenance cost.

New & Refurbished C-Arm Systems. Call 702.384.0085 Today!

KenQuest provides all major brands of surgical c-arms (new and refurbished) and carries a large inventory for purchase or rent. With over 20 years in the medical equipment business we can help you fulfill your equipment needs

The Walloon Region supports this 3-year agreement, called the BiDMed project (for Big Data in Medicine) through its Biowin health cluster.

Alexandru Dasu, Medical Physicist, Chief of Physics, Skandionkliniken, commented: “In order to maximize the benefits of proton therapy, we need to minimize the exposure of healthy tissue to the radiation dose. This pushes us to adapt our dose distribution plan as the tumor evolves throughout the course of treatment. This agreement will allow Skandionkliniken to continue to pioneer new ways of using the latest treatment course data to personalize treatment.”

Benoit Macq, Ph.D., UCL, commented: “UCLouvain is proud to be part of this venture. Our University wants to be a key partner in the digital transition of companies with a focus on the use of emerging tools of machine learning. The challenges proposed in BidMed will allow broadening our expertise in deep learning and cyberphysics. BidMed will treat large data sets and will be an exemplary use case of our research in algorithmic.”

Gery Gevers, Executive Vice President, Digital Solutions, IBA, commented: “IBA is constantly looking for ways to improve patient outcomes and reduce the access cost to proton therapy. We are proud to join forces with leading academic centers such as Skandionkliniken and UCL as well as with innovative digital companies such as Telemis to achieve this ambitious goal. We are also thankful to the Walloon Region and Biowin to support our efforts in offering innovative treatment delivery.”

Stephane Ketelaer, CEO of Telemis commented: “This agreement underlines our commitment to improving patient treatments by developing innovative medical imaging solutions and building strong relationships between medical technology leaders and internationally recognized university research centers.”

You Must Be Logged In To Post A Comment